Vaxcyte Phase 3 Data Strengthen VAX-31, but Two Trials Still Matter
VAX-31 met all prespecified OPUS-1 primary endpoints and broadened serotype coverage, supporting a best-in-class thesis while regulatory and manufacturing risk remain.
Vaxcyte's VAX-31 delivered the central result investors needed from OPUS-1: the pivotal adult Phase 3 trial met all prespecified primary immunogenicity endpoints. In adults aged 50 and older, the company said all 28 serotypes shared with Prevnar 20 and/or Capvaxive met the trial's noninferiority criterion, while the three serotypes unique to VAX-31 and cross-reactive serotype 20B met the superiority criterion. The data materially reduce clinical risk, but they do not complete the development program.
Why the serotype result matters
Pneumococcal conjugate vaccines protect against selected bacterial serotypes. Broader coverage is valuable only if immune responses to the established serotypes are preserved. VAX-31 is designed to cover 31 serotypes, so the investment thesis depends on adding breadth without diluting performance against strains already addressed by Pfizer's and Merck's products.
Vaxcyte reported that all shared comparisons cleared the prespecified threshold. Against the stricter benchmark involving Capvaxive, two comparisons did not meet that higher statistical bar, but they met the conventional threshold and did not prevent the study from achieving its primary objectives. That distinction should be preserved: the trial succeeded, while the detailed profile was not uniformly superior on every shared strain.
Safety was also supportive. The company described VAX-31 as well tolerated, with a profile similar to the comparator vaccines and common adverse events generally mild to moderate and resolving quickly. Topline safety is encouraging, although regulators will assess the complete dataset and manufacturing consistency rather than a press release alone.
The remaining development path
OPUS-2 evaluates administration with seasonal influenza vaccine, and OPUS-3 studies adults previously vaccinated against pneumococcal disease. Vaxcyte expects results from both in the first half of 2027. Those studies matter commercially because real-world adoption includes coadministration and previously vaccinated patients. The company also plans a manufacturing consistency study before a potential regulatory filing.
Vaxcyte reported $2.51 billion of cash, cash equivalents and investments at June 30, 2026, before the newly announced financing. That balance supports development and launch preparation, but the company remains pre-revenue and must scale manufacturing ahead of any approval.
OPUS-1 establishes a strong efficacy and breadth foundation. The next re-rating will depend on consistent follow-up data, regulatory alignment and the ability to manufacture a complex 31-valent vaccine at commercial scale. Investors should view the result as a major de-risking event, not the end of clinical, regulatory or execution risk.
Continue your PFE research
Related News
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Biotech Catalysts Put Moderna and Achieve Life Sciences in Focus
A dense clinical calendar gives investors several binary events, led by Moderna and Merck’s melanoma program and Achieve Life Sciences’ response to an FDA manufacturing rejection.
Bank OZK's Rising Dividend Is Well Covered, but Credit Still Sets the Limit
Bank OZK raised its quarterly dividend for a 65th straight quarter. A payout near one-third of earnings provides room, while construction-loan credit remains the main constraint.
Parabilis Heads Into ESMO With Strong Early Data and a High Bar
Parabilis will present updated zolucatetide data in desmoid tumors on Oct. 24. Early responses were strong, but investors still need durability, safety and a credible Phase 3 dose.
Pfizer's 5.8% Yield Depends on Cash Flow Catching Up
Pfizer's dividend remains covered by adjusted earnings, but 2025 free cash flow fell short of distributions. Debt and patent expirations leave management less room to restore dividend growth.
Three Stocks Hit New Lows, but the Risks Were Very Different
EyePoint Pharmaceuticals, CoreWeave and Eos Energy Enterprises all reached fresh 52-week lows on Oct. 19, but grouping them as one risk-off trade hides the important distinction. Each company is being tested by a different kind of execution problem.
EyePoint faced the most definitive setback. Its LUCIA Phase 3 trial of DURAVYU in wet age-related macular degeneration did not establish non-inferiority to aflibercept at weeks 52 and 56. The company said it would end the wet AMD program and cut about 53% of its workforce, targeting roughly $30 million in annual savings while expecting about $9 million of severance and related charges. Cash and equivalents were approximately $118 million at Sept. 30. EyePoint is preserving resources for DURAVYU studies in diabetic macular edema, but that program now carries much more of the company's value.
CoreWeave's problem is less binary. Second-quarter revenue reached $2.58 billion and backlog was about $104 billion, evidence that demand for AI computing remained strong. Yet net interest expense climbed to $640 million from $267 million a year earlier. The market is asking whether a rapidly growing cloud company can keep financing data centers on acceptable terms. That is a capital-structure question, not a demand collapse.
Eos Energy sits between those two cases. The battery maker projected preliminary third-quarter revenue of $82 million to $83 million, up roughly 19% to 21% sequentially and 169% to 172% from a year earlier. Shipments rose about 23% from the second quarter. Even so, management expected full-year revenue in the lower half of its prior $300 million to $350 million range, making the pace of its production ramp the central issue.
The contrast matters for investors. EyePoint must rebuild its clinical thesis after a failed pivotal program. CoreWeave must prove that contracted demand can outrun financing costs. Eos must turn higher shipments into reliable revenue and better margins as its second production line scales.
A shared low on a price chart does not mean a shared investment case. The next decisive evidence will come from clinical data at EyePoint, funding and cash conversion at CoreWeave, and manufacturing throughput at Eos.
Visa’s Valuation Depends More on Margin Expansion Than Sales Growth
Visa's October 16 closing price valued the company at 30.9 times the adjusted trailing earnings measure used by Trefis. Consensus estimates cited in that analysis reduce the multiple to 25.7 times fiscal 2027 earnings and 22.4 times fiscal 2028 earnings.
A falling forward multiple can look reassuring, but it only happens if the forecast profit arrives. The sales assumptions are not the hardest part. Consensus calls for revenue growth of 10.7% in fiscal 2027 and 10.4% in fiscal 2028, below the 14.4% growth reported for the 12 months through June 2026 in the source analysis.
The margin is the real assumption
Consensus expects fiscal 2028 net income to grow 14.7% while revenue grows 10.4%. It also models a 60.2% net margin in fiscal 2028, up from an estimated 56.6% in fiscal 2026. That 3.6 percentage-point expansion requires costs to rise more slowly than revenue over two years.
Management's fiscal fourth-quarter outlook, as cited by Trefis, gave only modest support for that gap. Visa guided net revenue to the high end of low-double-digit growth and operating expenses to low-double-digit growth. The company also discussed job reductions, but cost action must be large and durable enough to improve margins without weakening product investment.
Recent revenue included some items that may not repeat at the same pace. Management cited tax refunds, fuel spending, FIFA-related activity and Visa Direct in U.S. payment volume. Pismo and Newpay added a little under 1.5 percentage points to fiscal third-quarter revenue growth on the non-GAAP basis described in the original analysis.
The valuation therefore has two layers of risk. Payment volume and services must sustain roughly double-digit revenue growth, and expense growth must remain lower for consensus margin expansion to appear. A miss on either can keep the forward multiple from compressing as expected.
The next report should be read as a margin bridge, not only an earnings comparison. Revenue growth, incentives, personnel costs and acquisition contributions need to explain how Visa gets from current profitability to the consensus 2028 margin. Until then, the 22.4-times fiscal 2028 figure is a scenario, not an observed price.
Applied Digital’s Growth Story Now Hinges on Cash-Flow Timing
Applied Digital's 10% rebound followed a difficult stretch for AI-infrastructure stocks, but its investment case is increasingly about balance-sheet timing. The company is building large data-center campuses under long leases, which can create durable revenue only after construction milestones are met.
The scale is already visible. Applied Digital reported fiscal 2026 cash capital spending of roughly $2.87 billion and operating cash flow of about $89.7 million in the original analysis. At May 31, the company's earnings release listed $4.2 billion of cash, cash equivalents and restricted cash, compared with $5.0 billion of debt.
Those totals need careful interpretation. Restricted cash is often committed to construction accounts, debt service or letters of credit. It cannot be treated as fully interchangeable with unrestricted cash. Debt can also sit at project subsidiaries with different security and repayment terms, so a simple net-debt subtraction misses the timing of inflows and obligations.
Leases create visibility, not instant cash
Applied Digital has described 1.41 gigawatts of leased capacity and about $36 billion of initial contracted revenue in the source report. Those figures represent long-duration commitments rather than one year's sales. The economic value depends on delivering each building, collecting rent and financing tenant fit-out costs without excessive leakage to interest or new equity.
The company's fiscal first-quarter figures in the source showed revenue rising 322% and included $183.5 million of tenant fit-out revenue. Fit-out revenue can be substantial, but investors should separate it from recurring base rent because the margin, timing and capital requirements differ.
A useful cash-flow bridge starts with unrestricted cash, adds committed project funding and tenant contributions, then subtracts remaining construction, interest and corporate overhead. Management's disclosure of interest expense and lease-related revenue should make that bridge easier to test over successive quarters.
The next report should show delivered capacity, recurring lease revenue and remaining cost to complete by campus. If those numbers improve together, the backlog is becoming an operating business. If debt and restricted cash rise faster than energized capacity, the stock remains dependent on favorable capital markets.
A Roth IRA Is Not Automatically the Best Home for Every High-Yield Stock
A Roth IRA can shelter years of dividends and capital gains from current tax, and qualified withdrawals are generally tax-free. That makes it attractive for investments with high expected returns. It does not mean every high-yield stock belongs there.
The original portfolio example mixed Energy Transfer, Realty Income, Main Street Capital, Ares Capital and Verizon. Those securities do not produce the same type of income. Verizon dividends are generally eligible for qualified-dividend treatment when holding-period rules are met. REIT and business-development-company distributions can include ordinary income, capital gains and return of capital. Energy Transfer is a master limited partnership that typically issues a Schedule K-1.
The MLP complication
Partnership investments can generate unrelated business taxable income, or UBTI, inside an IRA. IRS instructions say an IRA may need its own Form 990-T when gross unrelated business income reaches $1,000 or more. That does not make every MLP unsuitable for a Roth, but it means the custodian, tax reporting and position size matter.
The simplified claim that all dividends in a taxable account face one ordinary-income rate is also wrong. The tax result depends on the distribution's character, the investor's bracket, holding period and state. Return of capital may reduce cost basis instead of creating immediate income, while qualified dividends may receive preferential federal rates.
Account space has an opportunity cost. The 2026 IRA contribution limit is $7,500, or $8,600 for people age 50 or older, before income-based Roth restrictions. Filling that limited space with a slow-growing yield stock can crowd out assets with higher expected long-term gains. A taxable account also provides easier access and can allow tax-loss harvesting.
The better decision is made at the portfolio level. Compare each holding's expected return, tax character, turnover and liquidity needs, then place the least tax-efficient assets in protected accounts when practical. MLPs deserve an additional UBTI and K-1 check before purchase.
Roth treatment can improve after-tax compounding, but tax savings do not rescue a weak security. Yield, balance-sheet risk and dividend durability still come first, and individual tax circumstances can justify professional advice.
Albertsons Seeks More Than $8 Billion From Kroger After Failed Deal
Albertsons is asking a Delaware court for more than $8 billion from Kroger after their $24.6 billion merger collapsed under regulatory pressure. The figure is a claim, not an award, and the trial that began October 19 will determine whether Kroger breached the companies' agreement and caused the alleged losses.
The dispute turns on which side bears responsibility for the failed antitrust remedy. Albertsons argues Kroger did not use the required efforts to obtain approval and pursued a divestiture plan that regulators and courts found inadequate. Kroger says it complied with the merger agreement, worked extensively with regulators and owes neither the $600 million termination fee nor the broader damages.
How the claim reaches $8 billion
The reported demand combines several categories. Albertsons seeks the $600 million termination fee, about $6.88 billion tied to the premium its shareholders would have received, and more than $1 billion of alleged tax and other adjustments. Those components should not be added to market value as though payment were certain. The court must decide whether each item is recoverable, supported and caused by Kroger's conduct.
Kroger's own filings describe counterclaims, including alleged damage to its business and reputation. Its May and August 2026 quarterly reports also confirm that the Delaware trial was scheduled for October 19. Albertsons' filings say the companies terminated the deal after federal and state courts blocked it in December 2024.
The legal exposure is asymmetric in a practical sense. Albertsons could receive a large payment if it proves its case, while Kroger could face cash costs and financing consequences. A defense win would remove that overhang but would not restore the merger or the operating plans built around it.
Investors should separate three questions: whether Kroger breached the contract, whether Albertsons can prove the claimed losses, and how much the court considers recoverable. A ruling on liability may not immediately settle the amount if damages require a separate analysis.
The most useful developments will be trial evidence about the divestiture strategy, the exact wording of the efforts covenant and the judge's treatment of the lost-premium theory. Until then, the $8 billion figure measures the size of Albertsons' demand, not the probability-weighted outcome.
Latest comments